Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Adierazpen geografikoek jatorrizko produktu baten izena eremu geografiko batetik babesten dute, eta adierazpen horri esker kalitate, ospe edo beste ezaugarri jakin batzuk ditu. Ezagutu zer diren, zein den erregistratzeko prozedura eta zer onura dituzten.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
186
resultados
Última actualización
12/12/2025 [07:58:00]
Resumen de: LU601924B1
A bear bile Chinese medicinal wine for health preservation and disease treatment, which is made of bear bile powder, red dates, wolfberries and white wine, throughout the whole formula of the invention, the compatibility is reasonable, and the effects of clearing heat, calming the liver, invigorating the spleen and stomach, nourishing the kidney and liver, etc. can be achieved, it can not only sterilize and reduce inflammation, but also improve human immunity and prevent virus invasion; it can be not only used externally for traumatic injuries (mechanical injuries and burns), skin diseases, sinusitis, fever, dizziness and other symptoms, but also taken internally for critical nasopharyngitis, excessive internal heat, diseases caused by viral infections (such as sore throat caused by COVID-19), cough, cold, toothache, oral diseases (including periodontitis, halitosis, oral ulcer) and so on.
Resumen de: WO2025250893A1
Provided herein are methods of analyzing antibody binding. In some embodiments, the methods comprise contacting a set of SARS-CoV-2 protein variant functionalized nanoparticles (MNPs) with a set of antibodies, and contacting a set of ACE2 protein functionalized nanoparticles (MNPs) with the set of antibodies and a set of competition probes that comprise the SARS-CoV-2 protein variant. In some embodiments, the methods also include detecting binding, if any, of the SARS-CoV-2 protein variant functionalized MNPs with the set of antibodies and binding, if any, of the ACE2 protein functionalized MNPs with the set of antibodies and the set of competition probes that comprise the SARS-CoV-2 protein variant. Related systems and kits are also provided.
Resumen de: US2025368651A1
Disclosed herein are compound of Formula I, Formula II, or Formula III: or a pharmaceutically acceptable salt and/or solvate of any one or more thereof, pharmaceutical compositions including such compounds, and methods of treating disease by administering or contacting a subject with one or more of the above compounds.
Resumen de: US2025368689A1
Embodiments provided here include engineered viral proteins, such as but not limited to coronavirus spike proteins, e.g., SARS-CoV-2 spike proteins. These engineered viral proteins comprise modifications or mutations that facilitate secretion and efficient production. Exemplary engineered coronavirus spike proteins of the disclosure can combine mutations in regions of the spike proteins observed in various viruses of concern that have circulated in humans in one singular protein sequence. Additional embodiments provide nucleic acid molecules encoding the coronavirus spike proteins of the disclosure, pharmaceutical compositions and host cells comprising the proteins and/or nucleic acid molecules described here, methods and uses thereof for the prophylactic treatment of infection or disease associated with a coronavirus infection, and methods of producing such coronavirus spike proteins, as well as provide neutralizing antibody titers representing SARS-CoV-2 variants of concern, and high throughput, large scale bioreactor operation methods for production of human vaccines based on purified Spike proteins.
Resumen de: US2025369049A1
The present disclosure relates to methods for detecting and staging cellular immune responses to viral infections, including to SARS-CoV-2 and to methods for treating viral infections.
Resumen de: WO2025246679A1
Provided are a broad-spectrum coronavirus-neutralizing antibody and a use thereof. The antibody CYFN1006-1 comprises a heavy chain variable region VH and a light chain variable region VL, wherein the VH comprises CDRH1 to CDRH3 having amino acid sequences as shown in SEQ ID NOs: 1-3; and the VL comprises CDRL1 to CDRL3 having amino acid sequences as shown in SEQ ID NOs: 4-6. CYFN1006-1 is a broad-spectrum highly-efficient coronavirus-neutralizing antibody, can efficiently neutralize all currently circulating SARS-CoV-2 variants, shows medium efficacy on SARS-CoV, and provides a new choice for solving the problems of viral escape and drug resistance encountered in the application of monoclonal antibody passive immunotherapy against novel coronavirus infection.
Resumen de: US2025367278A1
The disclosure provides coronavirus mRNA vaccines, including vaccines directed against spike proteins of one or more variant strains of SARS-CoV-2, as well as methods of using the vaccines.
Resumen de: US2025368767A1
Methacrylate-based functionalized dendronized polyglycerol polymers are provided. These polymers are highly biocompatible and less anticoagulant, form thread-like single chain fibers and show excellent inhibition against respiratory viruses such as SARS-CoV-2 and HSV-1. They can be easily used for forming degradable hydrogels together with a crosslinker.
Resumen de: US2025368755A1
Disclosed are a peptide specifically binding to a PPC region of a SARS-CoV-2 spike protein and a composition for preventing SARS-CoV-2 infection using the same. The peptide includes a peptide sequence of DGRARQSQDDD or GSQIALRRRDE.
Resumen de: US2025367270A1
Provided herein are, inter alia, peptides capable of binding viral proteins and thereby preventing viral infection, replication and spread (e.g., SARS CoV-2). The conjugates provided herein include a trimerizing domain (e.g., a collagen 18 trimerizing domain) attached through a peptide linker to a viral protein binding domain (e.g., a spike binding domain). The peptides and trimeric compositions provided herein exhibit a unique trimeric symmetry which results in superior binding affinities and low binding entropies providing for desirable compositions inhibit viral entry and treating viral infection.
Resumen de: US2025367225A1
The subject matter described herein relates to methods of zNKT cell activation by the 7DW8-5 glycolipid.
Resumen de: US2025345415A1
The present disclosure describes, inter alia, fusion polypeptides comprising a SARS-CoV-2 Spike polypeptide fragment comprising at least a portion of the N-terminal domain, domains CD1, RBM, and CD2, and at least a portion of CTD1, wherein the N- or C-terminus of the Spike polypeptide fragment is fused to a heterologous N- or C-terminal tag comprising at least two, at least three, or at least four amino acids, as well as polynucleotides and vectors expressing such fusion polypeptides, pharmaceutical compositions comprising the polypeptides or polynucleotides encoding them, host cells for their production, and methods of using such pharmaceutical compositions as vaccines or for generation of antibodies.
Resumen de: WO2024158875A1
Methods and compositions for treating SARS-CoV-2 and COVID-19 are disclosed. Sulfone-1H-pyrrole-2-carboxamides of the following formula inhibit the SARS-CoV-2 PLpro/NSP3 protein and are therefore useful for treating SARS-CoV-2 and COVID-19.
Resumen de: US12486316B1
The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-COV-2 and methods of making and using the same. The antibodies can be used, for example, in prophylaxis, post-exposure prophylaxis, or treatment of SARS-COV-2 infection. The antibodies can also be used to detect SARS-COV-2, e.g., an infection in subject.
Resumen de: MX2022009836A
SARS-CoV-2 S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the SARS-CoV-2 S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to SARS-CoV-2 S in a subject, for example, an immune response that inhibits SARS-CoV-2 infection in the subject.
Resumen de: MX2025009957A
The present disclosure provides multi ci str onic vaccines and method for producing and using the same in preventing infection or transmission, or reducing severity of disease caused by influenza and/or SARS-Cov-2 virus in a subject. Multicistronic vaccines of the disclosure can be administered via intramuscular, intranasal, or inhalation route. In one particular embodiments, the disclosure provides a recombinant adenovirus comprising at least two different extraneous oligonucleotides that are capable of stimulating an immune response in a subject. Each of the oligonucleotide independently comprises an oligonucleotide that encodes either influenza or SARS-Cov-2 virus antigens.
Resumen de: MX2025012626A
Disclosed herein are coronavirus (CoV) Spike (S) polypeptides, including naturally and non-naturally occurring polypeptides, and nanoparticles and immunogenic compositions comprising the same, which are useful for stimulating immune responses against various SARS-CoV-2 strains. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
Resumen de: US2025360134A1
The present invention relates to new specific 6-6 or 5-6 fused bicyclic compounds comprising pyrimidine or pyridine useful in the prevention and/or treatment of infectious diseases. In particular, the present invention relates to a compound of formula (I) wherein: Ar1 is a (C5-C11)arylene or (C5-C11)heteroarylene group, X is —CH—, —S—, —NR5 or —N—, Y is —CH—, —NR5—S— or —NR6—CH2—, T is —CH— and Q is —CH— or T is —N— and Q is —CR10— or —N—, provided that one or two of X, Q and Y comprise a heteroatom, and with the proviso that, at least one of R1, R2, and, if present, R5 or R6, contains a group —NH-Alk-NR3R4. The inventors showed that compounds of formula (I) present an activity against both W2 and 3D7 Plasmodium falciparum strains, an activity against T. brucei brucei but also an activity against SARS-CoV-2 virus, and that they are positive for G4 recognition. The invention also relates to the preparation process and to the therapeutic uses of the compounds of formula (I).
Resumen de: US2025362296A1
The invention relates to methods and kits for determining a SARS-CoV-2 strain in a sample. The invention also provides methods and kits for detecting a single nucleotide polymorphism (SNP) in a target nucleic acid, wherein the target nucleic acid is a SARS-CoV-2 nucleic acid. The invention further provides methods and kits for detecting one or more antibody biomarkers in a sample.
Resumen de: US2025360201A1
Pan-coronavirus vaccines for inducing efficient, powerful and long-lasting protection against all Coronaviruses infections and diseases, comprising multiple highly conserved large sequences which may comprise one or more conserved B, CD4 and CDS T cell epitopes that help provide multiple targets for the body to develop an immune response for preventing a Coronavirus infection and/or disease. In certain embodiments, the large sequences are conserved proteins or large sequences, e.g., sequences that are highly conserved among human coronaviruses and/or animal coronaviruses (e.g., coronaviruses isolated from animals susceptible to coronavirus infections).
Resumen de: US2025361316A1
Disclosed are a peptide, an antibody, or an antigen-binding fragment thereof, which specifically binds to an ACE2 (angiotensin-converting enzyme 2) receptor, and a composition for preventing SARS-CoV-2, the composition comprising the same. The peptide includes at least one peptide sequence selected from a group consisting of SEQ ID NO: 1 GHPVNSVLLDF, SEQ ID NO: 2 GHPRVNVGGDF, SEQ ID NO: 3 GVLGPRLLIDY and SEQ ID NO: 4 DGPINRTTIDY.
Resumen de: WO2025242732A1
The present invention relates to the treatment of the COVID-19, here, the inventors generated potent non-neutralizing pan-SARS-CoV-2 mAb, notably the antibody C10, targeting a conserved region of the virus. Noteworthy, C10 demonstrated remarkable efficacy in recognizing nearly all known variants of the virus and effectively binding infected cells. Leveraging this pan-SARS-CoV-2 mAb, they have engineered CAR-T cells capable of efficiently killing lung epithelial cells infected with the virus. Overall, their work identifies a pan-SARS-Cov-2 able to target bona fide infected cells and provides a proof-of-concept for the potential use of CAR-T cell therapy in combating SARS-CoV-2 infections. Their findings also highlight the potential of non-neutralizing mAbs in mediating immune protection against emerging infectious diseases. Thus, the present invention relates to anti-spike antibodies, particularly in a purified form or in an isolated form and their use to treat SARS-CoV-2. Particularly, the present invention is defined by the claims.
Resumen de: US2025361277A1
In alternative embodiments, provided is a protease-responsive and surface-potential-tunable peptide-conjugated AIEgens (EGTP) for TMPRSS2 selective imaging and accurate inhibitor screening, where EGTP comprises four segments: the first is a polyglutamic acid (Glu, E for short in EGTP) that increases the solubility, blocks the positive charges and cell-penetrating ability of PyTPE; the second comprises a spacer trimylglycine (GGG, G) designed to enhance probe flexibility and reduce steric hindrance for TMPRSS2-substrate interactions; the third component second comprises a TMPRSS2-responsive peptide (QAR, T), which can be cleaved by TMPRSS2 after QAR sequence; and the fourth second comprises a positive charged AIEgens (PyTPE, P). In alternative embodiments, provided are main protease (Mpro)-responsive and modular-peptide-conjugated probes for the selective imaging and inhibition of SARS-CoV-2 infected cells via enzyme-instructed self-assembly and aggregation-induced emission.
Resumen de: WO2024153586A1
The present invention relates to a new antisense oligonucleotide, a pharmaceutical composition comprising it and their use for preventing or treating infection by coronavirus, especially by SARS-CoV-2 virus which causes the infection disease COVID-19.
Nº publicación: EP4653011A1 26/11/2025
Solicitante:
WESTVAC BIOPHARMA CO LTD [CN]
WestVac Biopharma Co., Ltd
Resumen de: EP4653011A1
Provided in the present invention is a recombinant protein vaccine and/or an mRNA vaccine for preventing and/or treating infections of SARS-CoV-2 or a mutant thereof, and particularly provided is a method of using the mRNA vaccine and the recombinant protein vaccine. The vaccine can induce the generation of an antibody response and a cellular immune response in vivo to block the binding of the S protein of SARS-CoV-2 to the ACE2 receptor of host cells, so that the host resists coronavirus infections.
BOPI
Sede Electrónica
